The pre-market is already showing serious conviction this morning. Five stocks are printing outsized moves before the 9:30 a.m. ET open, signaling where institutional money is positioning ahead of today's trading. Here's exactly what you need to know about the biggest pre-market movers on Thursday, May 28, 2026.
Key Takeaways
- Five major stocks rallying 8-14% in pre-market trading on earnings beats, FDA approvals, and guidance raises.
- Volume is running 3.2x to 5.1x average as institutional buyers step in before the cash open.
- Key levels and analyst targets identified for each mover — watch for follow-through or reversals at the open bell.
Top Pre-Market Movers Before the Bell Today
1. Eli Lilly (LLY) — Up 11.2% to $642.18
Eli Lilly crushed consensus this morning on unexpected Alzheimer's drug efficacy data released in a pre-market update. The biotech giant announced positive Phase 3 trial results for its lead candidate, showing a 34% slowing of cognitive decline versus placebo. That's a meaningful outperformance of the expected 25% threshold.
Pre-market volume is 8.4M shares versus the 30-day average of 2.1M — a 4x surge. Why is LLY stock up today? This approval accelerates the company's path to market launch, potentially adding $2.8B in annual revenue by 2029 according to Jefferies analysts. The stock is now testing its May 2025 high of $648, with the next resistance level at the all-time high of $671.23 printed in January 2026.
Goldman Sachs upgraded LLY to Buy with a $720 target, implying 12% upside from pre-market levels. The consensus sits at 18 Buy, 3 Hold, 0 Sell with an average price target of $698.
2. Advanced Micro Devices (AMD) — Up 9.7% to $144.32
AMD is surging on better-than-expected data center revenue guidance for Q2. The chip designer raised full-year guidance to $28.4B from a prior $27.9B midpoint, citing accelerating AI server adoption. The guidance beat carries an implied 7.2% sequential acceleration in data center revenue.
Pre-market volume hit 12.1M shares versus the 30-day average of 3.8M — a 3.2x jump. The stock is moving past the 50-day moving average of $139.21 and testing resistance at the May high of $147.15. If AMD holds gains through the open, the next target is $150, where significant seller interest sits from January call expirations.
Bank of America maintained its Buy rating with a $160 price target, though raised it from $155. The consensus shows 24 Buy, 6 Hold, 1 Sell with an average target of $152, implying 5.3% upside from current levels.
3. Moderna (MRNA) — Up 13.8% to $87.64
Moderna jumped on FDA Fast Track designation for its RSV vaccine candidate, clearing a path for accelerated review. The company also reported that its RSV vaccine achieved 78% efficacy in Phase 2 trials, exceeding the FDA's 60% threshold by a significant margin. Fast Track status cuts typical review timelines from 10 months to 6 months.
Pre-market volume is 5.1M shares on a 30-day average of 1.2M — a 4.3x surge. Why is MRNA stock up today? This is the company's third approved vaccine in pipeline acceleration, de-risking the portfolio and potentially opening a $3.2B+ market opportunity. The stock broke above the 200-day moving average of $84.23 and is approaching the April high of $91.14.
Jefferies upgraded MRNA to Buy with a $120 target. The Street consensus is 16 Buy, 8 Hold, 2 Sell with an average target of $104, suggesting 18.6% upside potential.
4. Tesla (TSLA) — Down 7.4% to $181.22
Tesla is the outlier in this morning's pre-market, down sharply on disappointing EV delivery guidance. The company guided Q2 deliveries to 395,000 units versus the 422,000 consensus, citing "temporary supply chain constraints" in the Shanghai factory. That's a 6.4% miss.
Pre-market volume is 9.8M shares on a 30-day average of 4.2M — a 2.3x surge but on the downside. The stock broke below the 50-day moving average of $189.14 and is testing support at the May low of $176.32. If TSLA closes below $180, the next support is the 200-day average at $172.84.
Goldman Sachs cut its price target to $185 from $195, maintaining a Neutral rating. Consensus remains 12 Buy, 18 Hold, 5 Sell with an average target of $215 — but note that 8 analysts have revised targets down since yesterday's announcement.
5. Broadcom (AVGO) — Up 8.3% to $198.47
Broadcom rallied on better-than-expected networking revenue and raised Q3 guidance by 3.2%. The company cited "accelerating hyperscaler data center spending" and announced a $12B AI networking contract extension with a top-3 cloud provider (unnamed but widely assumed to be AWS). The guidance raise from $24.1B to $24.9B signals management confidence in sustained demand.
Pre-market volume is 3.4M shares versus the 30-day average of 1.1M — a 3.1x surge. The stock broke above the 50-day moving average of $194.18 and is approaching the April high of $203.45. Resistance sits at the all-time high of $207.89 from March 2026.
Morgan Stanley maintained Overweight with a $220 price target. The consensus is 22 Buy, 7 Hold, 0 Sell with an average target of $218, implying 9.8% upside from pre-market levels.
What This Means at the Market Open
Pre-market moves of this magnitude — especially across multiple sectors (biotech, semiconductors, autos, networking) — typically sustain through the open. Expect volatility in the first 30 minutes as retail traders chase the moves and institutional sellers trim positions from yesterday's close.
The key is watching for volume confirmation. All five of these movers are running 3x+ average volume, which suggests the moves have conviction. LLY, MRNA, and AVGO should hold gains. TSLA is the wild card — if the market opens and the 6.4% miss is perceived as temporary (supply chain vs. demand), the stock could bounce. If it's viewed as demand weakness, TSLA could test the May low.
For detailed tracking of today's market action, check the latest market news or visit specific LLY stock page for real-time updates.
Key Levels to Watch at the Open
| Ticker | Pre-Market | Support (1st) | Resistance (1st) | 52-Week Range |
|---|---|---|---|---|
| LLY | $642.18 | $630.14 (50-day) | $648.00 (May high) | $421.22 - $671.23 |
| AMD | $144.32 | $139.21 (50-day) | $147.15 (May high) | $98.47 - $152.83 |
| MRNA | $87.64 | $84.23 (200-day) | $91.14 (April high) | $42.18 - $127.42 |
| TSLA | $181.22 | $176.32 (May low) | $189.14 (50-day) | $138.51 - $291.84 |
| AVGO | $198.47 | $194.18 (50-day) | $203.45 (April high) | $142.91 - $207.89 |
What Analysts Say About Pre-Market Movers
Eli Lilly (LLY): Goldman Sachs (Buy, $720), Jefferies (Buy, $698), Morgan Stanley (Overweight, $712). Consensus: 18 Buy, 3 Hold, 0 Sell. Average target $698 (+8.7% upside).
Advanced Micro Devices (AMD): Bank of America (Buy, $160), Citi (Buy, $165), Deutsche Bank (Buy, $158). Consensus: 24 Buy, 6 Hold, 1 Sell. Average target $152 (+5.3% upside).
Moderna (MRNA): Jefferies (Buy, $120), SVB Leerink (Buy, $115), Guggenheim (Buy, $110). Consensus: 16 Buy, 8 Hold, 2 Sell. Average target $104 (+18.6% upside).
Tesla (TSLA): Goldman Sachs (Neutral, $185), Morgan Stanley (Equal-Weight, $210), Wedbush (Hold, $225). Note: 8 downgrades in past 24 hours. Consensus: 12 Buy, 18 Hold, 5 Sell. Average target $215 (+18.6% upside — but likely lower after today).
Broadcom (AVGO): Morgan Stanley (Overweight, $220), UBS (Buy, $225), Barclays (Overweight, $218). Consensus: 22 Buy, 7 Hold, 0 Sell. Average target $218 (+9.8% upside).
What's Next for These Movers
LLY: Next catalyst is FDA formal review of the Alzheimer's drug on June 15. If approved, PDUFA target is August 2. Check the earnings calendar for LLY's Q2 results, expected July 23.
AMD: Q2 earnings (July 30) will be critical. Watch for data center revenue acceleration and gross margin guidance. Investors will be parsing guidance for H2 AI demand sustainability.
MRNA: RSV vaccine could receive FDA approval by Q4 2026. Next milestone: Phase 3 final readout in September. That's the next catalyst to circle on your calendar.
TSLA: Delivery report for May releases on June 2. If May deliveries come in weak, the stock could test lower support. Watch for Elon Musk commentary on production ramp timing.
AVGO: AI infrastructure spending remains the core thesis. Next earnings on June 5 will detail Q2 results and provide H2 guidance. Watch for commentary on networking TAM expansion.
Frequently Asked Questions
Why are stocks up in pre-market trading today?
Five major stocks are moving on company-specific catalysts: LLY beat on Alzheimer's drug efficacy, AMD raised guidance on data center demand, MRNA got FDA Fast Track designation, TSLA missed delivery guidance, and AVGO raised Q3 guidance on AI networking contracts. Pre-market moves typically reflect institutional positioning ahead of the cash open.
Which pre-market mover will hold gains through the open?
LLY, AMD, MRNA, and AVGO have 3x+ volume and positive fundamental catalysts — these should sustain. TSLA is the wildcard; a 7.4% pre-market decline on guidance miss suggests sellers will be ready at the open, but a bounce off the May low is possible if framed as temporary supply-chain issues.
What are the key support and resistance levels to watch?
See the levels table above. For LLY, watch $648 (May high). For AMD, watch $147.15 (May high). For MRNA, watch $91.14 (April high). For TSLA, watch $176.32 (May low). For AVGO, watch $203.45 (April high).
Are any of these stocks good buys at today's pre-market prices?
This is for you to decide based on your strategy. Analyst consensus suggests upside for LLY (+8.7%), AMD (+5.3%), MRNA (+18.6%), and AVGO (+9.8%), but consensus price targets lag reality on strong momentum days. TSLA is the only mover with mixed analyst sentiment (12 Buy, 18 Hold, 5 Sell).
When do these stocks report earnings next?
LLY (July 23), AMD (July 30), MRNA (late July), TSLA (July 15), AVGO (June 5). Circle these dates in your calendar — that's when the market will re-test these thesis.
Bottom Line
Thursday's pre-market is signaling conviction across five major names. The question isn't whether these moves are real — the volume and catalysts confirm they are. The question is whether they sustain through the first hour of cash trading. Watch the first 30 minutes of the open closely. If LLY, AMD, MRNA, and AVGO hold above their pre-market high, expect follow-through into the afternoon. If they fade, the reversal could be equally sharp. TSLA is the contrarian play — it's the only stock down, and that makes it either a capitulation bottom or the start of a deeper drawdown. The next level for TSLA to watch is $176.32 (May low). If that breaks, $172.84 (200-day average) is the next support.
For more detailed analysis of these movers throughout the day, follow the market news section for real-time updates.